Related Experiment Video

Updated: Jun 8, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Prevention of type 1 diabetes: today and tomorrow

Simona Cernea1, Minodora Dobreanu, Itamar Raz

  • 1Diabetes, Nutrition and Metabolic Diseases Outpatient Unit, Târgu Mureş Emergency County Clinical Hospital, 50Gheorghe Marinescu Str., Târgu Mureş, Romania. simonacernea@yahoo.com

Diabetes/Metabolism Research and Reviews
|October 12, 2010
PubMed

Insights

Therapeutic interventions for type 1 diabetes aim to halt autoimmune attacks and restore insulin-producing beta cells. Current therapies offer short-term benefits, suggesting combination treatments are key for long-term success.

Area of Science:

  • Immunology
  • Endocrinology
  • Diabetology

Background:

  • Type 1 diabetes involves pathogenic autoreactivity targeting beta cells.
  • Maintaining beta-cell mass and function is crucial for metabolic control.
  • Therapeutic strategies target primary, secondary, or tertiary prevention.

Purpose of the Study:

  • To review therapeutic interventions for type 1 diabetes.
  • To assess the efficacy of current immunotherapies.
  • To identify future therapeutic directions.

Main Methods:

  • Review of clinical trials for type 1 diabetes therapies.
  • Analysis of antigen-specific and non-specific immune therapies.
  • Evaluation of short-term and long-term outcomes.

Main Results:

  • Antigen-specific (e.g., GAD65) and non-specific (e.g., anti-CD3) immunotherapies show short-term modulation of autoimmunity.
  • These therapies help prevent insulin secretion loss post-diagnosis.
  • No single long-term effective therapy has been identified.

Conclusions:

  • Current immunotherapies provide limited short-term benefits for type 1 diabetes.
  • A combination approach is likely necessary for effective long-term management.
  • Future strategies may involve immunotherapy combined with islet regeneration or replacement.

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-1906:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.